Related Experiment Video
Updated: May 12, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
Relationship between endothelial nitric oxide synthase gene polymorphisms and ischemic stroke: a meta-analysis
1Department of Neurology, The First Hospital of Jilin University, Changchun, China.
Acta Neurologica Scandinavica
|April 9, 2013
Summary
Genetic variations in the endothelial nitric oxide synthase (eNOS) gene, specifically G894T and 4b/a, increase ischemic stroke risk in Asian populations. The T786C polymorphism also shows an association with ischemic stroke in Asians.
Area of Science:
- Genetics and Molecular Biology
- Neurology
- Cardiovascular Research
Background:
- Conflicting results exist regarding the association between endothelial nitric oxide synthase (eNOS) gene polymorphisms (G894T, 4b/a, T786C) and ischemic stroke.
- Understanding these genetic associations is crucial for identifying individuals at higher risk for ischemic stroke.
Purpose of the Study:
- To conduct a comprehensive meta-analysis investigating the association between three specific eNOS gene polymorphisms and ischemic stroke risk.
- To clarify the conflicting findings from previous individual studies.
Main Methods:
- A systematic literature search was performed up to April 30, 2012.
- Meta-analysis was conducted using fixed or random effects models to calculate pooled odds ratios (ORs).
- Data from 33 publications, including over 5000 cases and controls for each polymorphism, were analyzed.
Main Results:
- In Asian populations, the G894T and 4b/a polymorphisms were significantly associated with an increased risk of ischemic stroke (dominant models: OR = 1.58 and 1.46, respectively).
- The T786C polymorphism was also significantly associated with ischemic stroke risk in Asians (dominant model: OR = 1.17; additive model: OR = 1.18).
- In white populations, the aa genotype of the 4b/a polymorphism appeared to be protective against ischemic stroke (recessive model: OR = 0.44).
Conclusions:
- The G894T, 4b/a, and T786C polymorphisms in the eNOS gene are confirmed to be associated with ischemic stroke risk in Asian populations.
- The 4b/a polymorphism may play a contrasting role in ischemic stroke risk between Asian and white populations.
More Related Videos
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...